Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception.

Frontiers in immunology - 1 Jan 2026

Liang Zhanhao, Zhao Xutong, Jiang Mingru, Zhou Meizhu, Cheng Miao, Liu Shibiao, Zhao Yi

Abstract excerpt

Therapeutic failure in EGFR-mutant non-small cell lung cancer (NSCLC) is commonly viewed as a consequence of acquired resistance, but this perspective may overlook an earlier and potentially more tractable phase marked by the survival of residual cells after effective EGFR inhibition. In this Review, we define the mitochondrial niche as a temporally bounded, hypothesis-generating model of early residual disease...

Read the complete abstract on PubMed

Topics

Humans
Mitochondria
ErbB Receptors
Mutation
Lung Neoplasms
Neoplasm, Residual

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Carcinoma, Non-Small-Cell Lung

Animals

Tumor Microenvironment

Drug Resistance, Neoplasm

Source

Open in PubMed Open full text

Identifiers

PMID: 42707563
DOI: 10.3389/fimmu.2026.1908826
PMCID: PMC13548500

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mitochondrial niches of residual disease in EGFR-mutant NSCLC: immune-constrained persistence and therapeutic interception.PMID 42707563Read ↗

Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Distinct Spatial Programs of Response versus Resistance in Non-Small Cell Lung Cancer after Neoadjuvant ChemoimmunotherapySemantic proximity Read ↗

Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming.Semantic proximity Read ↗

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.Semantic proximity Read ↗

Single-Cell Analysis Reveals Transcriptomic Features of Drug-Tolerant Persisters and Stromal Adaptation in a Patient-Derived EGFR-Mutated Lung Adenocarcinoma Xenograft Model.Semantic proximity Read ↗

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies.Semantic proximity Read ↗

Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programsSemantic proximity Read ↗

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous MutatorsSemantic proximity Read ↗

Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapySemantic proximity Read ↗

A four‑gene signature identifies TKI‑induced persister cells and uncovers a ZLN005‑induced pyroptotic vulnerability via the GSDME pathway in EGFR‑mutant lung cancer.Semantic proximity Read ↗

ResMap: A community resource for systematic mapping of therapy-persistent residual cancer cell dependencies across contexts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.